The phase 3 NETTER-1 study of (177)Lu-DOTATATE in patients with midgut neuroendocrine tumors: Updated progression-free survival analyses Meeting Abstract


Authors: Kunz, P. L.; Benson, A.; Bodei, L.; Grande, E.; Mittra, E.; Kulke, M. H.; Yao, J. C.; Wolin, E. M.; Niepel, D.; Demange, A.; Krenning, E. P.; Strosberg, J. R.
Abstract Title: The phase 3 NETTER-1 study of (177)Lu-DOTATATE in patients with midgut neuroendocrine tumors: Updated progression-free survival analyses
Meeting Title: 14th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society (NANETS 2021)
Journal Title: Pancreas
Volume: 51
Issue: 3
Meeting Dates: 2021 Nov 4-6
Meeting Location: Virtual
ISSN: 0885-3177
Publisher: Lippincott Williams & Wilkins  
Date Published: 2022-03-01
Start Page: E44
End Page: E45
Language: English
ACCESSION: WOS:000819123700063
PROVIDER: wos
PUBMED: 35584389
DOI: 10.1097/MPA.0000000000001979
Notes: Meeting Abstract: C-32 -- Located in section labeled "Clinical" -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lisa   Bodei
    205 Bodei